辛热类毒性中药临床应用的风险效益“阈”探索

doi:10.19803/j.1672-8629.2021.06.05

摘要/Abstract

摘要： 目的开展毒性中药风险效益“阈”研究,为该类中药的应用提供客观参考依据。方法以辛热类毒性中药川（草）乌用药为示例,综合多准则决策、Meta分析、熵权法等手段,建立契合中药复杂用药特点的效益-风险评价（benefit-risk assessment, BRA）模型,开展基于评价结果的“阈”探索,发现影响毒性中药效-毒表达的关键因素,并量化区间范围。结果建立了较为稳定的示例药在其优势治疗领域应用的BRA模型,基于纳入的随机对照试验评价不同“阈”条件及区间范围对示例药效益-风险表达的影响,进而筛选到证候是影响示例药临床应用的关键核心条件。结论基于BRA开展的风险效益“阈”研究,可为临床提供合理使用毒性中药的客观依据,并开展针对性的预警防范。

关键词: 风险-效益, 阈, 辛热类毒性中药, 川乌, 草乌

Abstract: Objective To study the "risk-benefit threshold" of toxic herbs and provide objective reference for their application. Method Taking Radix aconiti Sinensis and Radix aconiti Kusneziffii (Chuanwu and Caowu) with acrid, hot and toxic properties as an example, a benefit-risk assessment (BRA) model was established by integrating multi criteria decision-making, meta analysis and entropy weight method. The "threshold" exploration based on the evaluation results was carried out, and the key factors affecting the expression of efficacy and toxicity in toxicity were found and the range of interval was quantified. Result A relatively stable BRA model was established to evaluate the effect of different "threshold" conditions and intervals on the benefit risk expression of sample drugs based on the included randomized controlled trials. Conclusion "risk- benefit threshold" could provide objective basis for the rational use of toxic herbs, and also could carry out targeted early warning and prevention.

Key words: risk-benefit, threshold, herbs with acrid, hot and toxic properties, Radix Aconiti Sinensis, Radix Aconiti Kusneziffii

中图分类号:

R969.3

张晓朦, 张冰, 张丹, 林志健. 辛热类毒性中药临床应用的风险效益“阈”探索[J]. 中国药物警戒, 2021, 18(6): 514-519.

ZHANG Xiaomeng, ZHANG Bing, ZHANG Dan, LIN Zhijian. Exploration the "Risk-Benefit Threshold" of Chinese herbs with Acrid, Hot and Toxic Properties[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 514-519.

参考文献

[1] Working CIOMS Group Ⅳ. benefit-risk balance for marketed drugs: evaluating safety signals [R]. Geneva: Council for International Organizations of Medical Sciences, 1998.
[2] Christine R, Elaine M, Kenneth H, et al.Benefit-risk assessment, communication, and evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist[J]. Pharmacoepidemiology and Drug Safety, 2015, 24: 1233-1240.
[3] The State Council of the People's Republic of China. Notice of the state council on issuing the national drug safety "twelfth five-year" plan [EB/OL]. (2012-01-12) [2021-01-05]. http://www.gov.cn/zwgk/2012-02/13/content_2065197.htm.
[4] The State Council of the People's Republic of China. Notice of the state council on printing and distributing the "thirteenth five-year" national food safety plan and the "thirteenth five-year" national drug safety plan [EB/OL]. (2017-02-14) [2021-01-05]. http://www.gov.cn/zhengce/content/2017-02/21/content_5169755.htm.
[5] National Medical Products Administration. The comprehensive department of national medical products administration for public consultation on the "Pharmacovigilance quality management standard" [EB/OL].(2021-05-13)[2021-05-13]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[6] Gao G.Evaluation method of comprehensive analysis of drug benefit risk[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2012, 21(11): 569-573.
[7] Zhang Y, Liu C, Wang SY, et al.Research on benefit risk evaluation system and main points of evaluation at home and abroad[J]. Central South Pharmacy(中南药学), 2018, 16(3): 427-432.
[8] Lu YM, Zhang MH, Wu ZA.Overview of drug benefit-risk assessment research progress[J]. Chinese Journal of Pharm-acovigilance(中国药物警戒), 2013, 10(8): 473-477.
[9] Li MC, Liu X, Liu BG.Drug benefit and risk assessment management[J]. Pharmaceutical Journal of Chinese People's Liberation Army(解放军药学学报), 2010, 26(2): 178-179.
[10] Mt-Isa S, Hallgreen CE, WangN, et al. Balancing benefit and risk of medicines: a systematic review and classification of available method-ologies[J]. Pharmacoepidemiology and Drug Safety, 2014, 23: 667-678.
[11] Hughes D, Waddingham E, Mt-Isa S, et al.Recommendations for benefit-risk assessment methodologies and visual representations[J]. Pharmacoepidemiology and Drug Safety, 2016, 25: 251-262.
[12] Guo JJ, Pandey S, Doyle J, et al.A Review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group[J]. Value in Health, 2010, 13(5): 657-666.
[13] Jiang H, Zhang XM, Zhang B, et al.Benefit and risk of tripterygium glycosides tablets in treatment of rheumatoid rheumatoid arthritis based on multi-criteria decision-making analysis[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(4): 798-808.
[14] Zhang XM, Jin YN, Zhang B, et al.Aconitum in treatment of rheumatoid arthritis: benefit-risk assessment[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(2): 234-241.
[15] Zhang XM, Lin ZJ, Zhang B, et al.Comparison of aconitum with tripterygium in treatment of axial spondyloarthritis: a benefit-risk assessment[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(2): 103-109.
[16] Chen ZW, Sun J, Li YM, et al.Efficacy of Shenshi Qianghuo Dihuang decoction in rheumatoid arthritis: a randomized controlled trial[J]. Journal of Integrative Medicine(中西医结合学报), 2010, 8(1): 35-39.
[17] Chen ZL, Zhang S.Curative effect observation of modified Guizhi Shaoyao Zhimu decoction and Yishen Chushi Pills in treating rheumatoid arthritis[J].Chinese Traditional Patent Medicine(中成药), 2017, 39(7): 1539-1541.
[18] Dong MJ, Jiang CQ, Gao JZ.Clinical study on treatment of rheumatoid arthritis with acupuncture and Xibikang decoction[J]. Shandong Journal of Traditional Chinese Medicine(山东中医杂志), 2010, 29(7): 465-467.
[19] Fan HM, Yuan BH.Curative effect observation of Guizhi Shaoyao decoction in the treatment of rheumatoid arthritis[J].Journal of Qiqihar Medical University(齐齐哈尔医学院学报), 2012, 33(19): 2636-2637.
[20] Gu YM, Ding XR.Observation of TCM internal and external with etanercept on the treatment of rheumatoid arthritis[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2010, 37(9): 1726-1728.
[21] Guo F, Zheng XM, Xie SH.Efficacy observation on treating 72 cases of RA in the integrative medicine[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2012, 4(6): 69-70.
[22] Hu JW, Zhang PN.Effect of treatment of cold dampness blockage type rheumatoid rthritis with combination of TCM and Western Medicine[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2016, 9(8): 1-2, 13.
[23] Jiang X.Effect and survival quality observation of the Bitongling Apoz-em used to treat rheumatoid arthritis of cold-dampness type[D]. Nan-jing: Nanjing University Of Chinese Medicine, 2007.
[24] Jiang D, Wu J.Analysis and evaluation of the efficacy of Chinese medicine self-made prescriptions combined with Antirheumatic Drugs in the treatment of active rheumatoid arthritis[J]. Journal of Modern Medicine & Health(现代医药卫生), 2016, 32(22): 3507-3510.
[25] Li FY.36 Cases of juvenile rheumatoid arthritis treated with integrated traditional Chinese and western medicine[J]. Chinese Journal of Applied Clinical Pediatrics(实用儿科临床杂志), 2004, 19(11): 1004-1005.
[26] Li X.Clinical observation on therapy of rheumatoidarthritis with arthragia-blockade syndrome by means of warming and smoothing meridian[J]. Journal of Liaoning University of Traditional Chinese Medicine(辽宁中医药大学学报), 2010, 12(11): 152-154.
[27] Li GD.Experience in the treatment of rheumatoid arthritis with integr-ated traditional Chinese and western medicine[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2011, 38(1): 118-119.
[28] Li XL, Deng GZ, Li J.Clinical observation on 41 cases of rheumatoid arthritis treated with integrated traditional Chinese and western medicine[J]. Journal of Practical Traditional Chinese Medicine(中医药导报), 2014, 20(16): 62-65.
[29] Li WH.Rheumatic arthralgia parallel randomized controlled study Aconitum treated[J]. Journal of Practical Traditional Chinese Internal Medicine(实用中医内科杂志), 2015, 29(8): 9-10.
[30] Liang JM.Kindhearted yiyiren decoction in the treatment of rheumatoid Arthritis clinical research[D]. Wuhan: Hubei University Of Traditional Chinese Medicine, 2012.
[31] Liu YN.Clinical observation of rheumatoid arthritis treated with Sanxiao yinzi Decoction combined with leflunomide[J]. Journal of Hunan University of Chinese Medicine(湖南中医药大学学报), 2011, 31(6): 17-18,20.
[32] Lu WJ.Clinical study of Warming Yang, Dispelling Cold, Tonifying Qi and Dredging Collaterals method in the treatment of rheumatoid arthritis[J]. Acta Chinese Medicine(中医学报), 2014, 29(10): 1525-1527.
[33] Luo SJ.The curative effect observation of modified aconiti decoction on reactiveness rheumatoid arthritis[J]. Acta Chinese Medicine(河南中医学院学报), 2009, 24(4): 71-72.
[34] Ma WK, Zhong Q, Yao JM, et al.Effect of the Jinwu Jiangu decoction for rheumatoid arthritis with methotrexate resistance[J]. Journal of Traditional Chinese Medicine(中医杂志),2010, 51(11): 993-995.
[35] Mai TX.Influence of integrated traditional Chinese and western medicine treatment and nursing on the clinical efficacy of active rheumatoid arthritis[J]. Journal of Frontiers of Medicine(医药前沿), 2013 (19) : 137-138.
[36] Mao LZ, Huang LH, Wu DQ.Effect and nursing of erteng aconite decoction for rheumatoid arthitis in activity[J]. Heilongjiang Medical Journal(黑龙江医学), 2013, 37(3): 220-222.
[37] Zhu JH.Observation on curative effect of Guizhi Shaoyao Zhimu decoction and Juanbi decoction in treating rheumatoid arthritis[J]. Shaanxi Journal of Traditional Chinese Medicine(陕西中医), 2014, 35(8): 984-986.
[38] Piao WJ.Clinical observation on treating rheumatoid arthritis with comprehensive therapy of traditional Chinese medicine[J]. Guide of China Medicine(中国医药指南), 2014, 12(34): 280-281.
[39] Shi L.Clinical study on treatment of rheumatoid arthritis with Tongbi No. 2[D].Wuhan: Hubei University Of Traditional Chinese Medicine, 2006.
[40] Sun W, Sun Y.Clinical observation on efficacy of integrative medicine in 48 cases of rheumatoid arthritis patients[J]. China Modern Doctor(中国现代医生), 2011, 49(12): 58-59.
[41] Tang W.Clinical observation on the treatment of 30 cases of rheumatoid arthritis[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy(中医药导报), 2011, 17(4): 67-68.
[42] Tian Q.Treatment of 30 cases with cold and dampness Bi syndrome by modified Wutou decoction[J]. Clinical Journal of Chinese Medicine(中医临床研究) , 2014, 6(24): 55-56.
[43] Wang GQ, Yan MH.30 Cases of rheumatoid arthritis treated by Fengshi decoction[J]. Medical Innovation of China(中国医学创新), 2010, 7(30): 65-66.
[44] Wang HT.Clinical observation of treatment of rheumatoid arthritis with Sisheng Juanbi Decoction[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2015, 7(9): 79-81.
[45] Wang LS.Clinical study on Wenbi Decoction in treating rheumatoid arthritis of Cold-Dampness Blocking Type[D]. Zhengzhou: Henan University of Chinese Medicine, 2016.
[46] Yu JW, Liu FD, Zhang WB.Clinical observation on 46 cases of rheumatoid arthritis treated with integrated traditional Chinese and western medicine[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy(中国民族民间医药), 2014, 23(11): 56-57.
[47] Zhang XL.Clinical observation on treatment of rheumatoid arthritis with Dihuang mixture[J]. Chinese Journal of Medicinal Guide(中国医药导刊), 2010, 12(8): 1383-1384.
[48] Zhang PK, Zhang GS, Yang KP.Clinical observation on the treatment of cold-dampness-blockage-type rheumatoid arthritis with Qubi Tang[J]. Combing Small-dose Methotrexate(风湿病与关节炎), 2016, 5(4): 25-27.
[49] Zheng XM, Mao LZ, Mai TX, et al.Clinical study on Erteng Wutou decoction in the treatment of active rheumatoid arthritis[J]. Shandong Journal of Traditional Chinese Medicine(山东中医杂志), 2012, 31(9): 636-638.
[50] Zhu YC, Huang LH.The curative effect and nursing of Chinese medicine Aconitum in treating rheumatoid arthritis[J]. Chinese General Practice Nursing(全科护理), 2009, 7(33): 3023-3024.